Rick Pauls
Principal executive officer pay for Rick Pauls, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
DiaMedica Therapeutics Inc. (DMAC) FY2023–FY2025
Aligned: paid up as stock roseCAP $1,424,344→$5,277,304 while $100 invested went $180.00→$504.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $1.2M | $1.4M |
| FY2024 | $1.6M | $2.4M |
| FY2025 | $2.7M | $5.3M |
The company's "$100 invested" index ran $180.00 at FY2023 → $504.00 by FY2025 — an annualized return of 67.3%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 67.3%/yr at DMAC ( FY2023–FY2025). See the CEO track-record ranking for context.